Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Sino Biopharmaceutical's Enterprise Value is $10,251 Mil.
Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $1,009 Mil. Therefore, Sino Biopharmaceutical's EV-to-EBIT ratio for today is 10.16.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Sino Biopharmaceutical (OTCPK:SBMFF) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBIT for the trailing twelve months (TTM) ended in Dec. 2025 was $1,009 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Sino Biopharmaceutical's EV-to-EBITDA for today is:
Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's EBITDA for the trailing twelve months (TTM) ended in Dec. 2025 was $1,009 Mil.
Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Revenue for the trailing twelve months (TTM) ended in Dec. 2025 was $4,472 Mil.
Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Cash Flow from Operations for the trailing twelve months (TTM) ended in Dec. 2025 was $1,311 Mil.
Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil.
For company reported semi-annually or annually, GuruFocus uses latest annual data as the TTM data. Sino Biopharmaceutical's Free Cash Flow for the trailing twelve months (TTM) ended in Dec. 2025 was $1,070 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical Enterprise Value Related Terms
Sino Biopharmaceutical Enterprise Value Historical Data
* Premium members only.
The historical data trend for Sino Biopharmaceutical's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
SBMFF vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Sino Biopharmaceutical's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Sino Biopharmaceutical Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Sino Biopharmaceutical's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Sino Biopharmaceutical's Enterprise Value falls into.
Sino Biopharmaceutical Enterprise Value Calculation
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Sino Biopharmaceutical's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Sino Biopharmaceutical (SBMFF) has a Enterprise Value of $10,251 Mil as of Jun. 29, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sino Biopharmaceutical and its competitors.
Is Sino Biopharmaceutical's Enterprise Value too high?
Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil. Overall, Sino Biopharmaceutical has a GF Score™ of 62/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Sino Biopharmaceutical's Enterprise Value compare to VRTX and REGN?
Sino Biopharmaceutical's Enterprise Value of $10,251 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Sino Biopharmaceutical and its competitors. Sino Biopharmaceutical's current Enterprise Value is $10,251 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Sino Biopharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Sino Biopharmaceutical (SBMFF) is currently considered Modestly Undervalued. The stock's GF Value™ is $0.67, compared to a current price of $0.60 — trading 10.2% below its estimated fair value. The current Enterprise Value is $10,251 Mil. Sino Biopharmaceutical's overall GF Score™ is 62/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Sino Biopharmaceutical (SBMFF), the current Enterprise Value is $10,251 Mil as of Jun. 29, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Sino Biopharmaceutical (SBMFF) Overvalued in 2026?
Based on GuruFocus' analysis, Sino Biopharmaceutical stock appears to be undervalued.
The current stock price of $0.60 is trading 10.2% below its estimated GF Value™ of $0.67.
GuruFocus considers Sino Biopharmaceutical to be Modestly Undervalued.
Key valuation signals for SBMFF:
Enterprise Value: $10,251 Mil
GF Value™: $0.67 vs. price of $0.60 (10.2% below fair value)
No single metric tells the full story. See the SBMFF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Sino Biopharmaceutical Ltd is an investment holding company. The company and its subsidiaries are principally engaged in the research and development, production and sale of a series of pharmaceutical products. Its business covering the entire industrial chain of R&D, production and commercialization of drugs, biological products and high-end generic drugs. The company's therapeutic areas include: oncology, liver disease, respiratory, and surgery/pain relief. The company's revenue was generated from the sale of pharmaceutical products in the Chinese mainland.
62GF Score
Get the complete analysis for SBMFF
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
SBMFF has been successfully added to your 
